Athira Pharma Q3 EPS $(0.87) Misses $(0.81) Estimate
Portfolio Pulse from Benzinga Newsdesk
Athira Pharma reported Q3 losses of $(0.87) per share, missing the analyst consensus estimate of $(0.81) by 7.41%. This represents a 64.15% increase in losses compared to the same period last year.
November 09, 2023 | 10:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Athira Pharma's Q3 earnings were worse than expected, with losses per share of $(0.87) compared to the estimated $(0.81). This is a significant increase in losses compared to the same period last year.
Athira Pharma's Q3 earnings missed analyst estimates, which is typically a negative signal for the stock. The increase in losses compared to the same period last year further exacerbates this negative impact. This could lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100